Danaher Corporation $DHR Stock Acquired by Riverbridge Partners LLC

Riverbridge Partners LLC boosted its holdings in Danaher Corporation (NYSE:DHR) by 9.0% in the 3rd quarter, Holdings Channel reports. The firm owned 243,517 shares of the conglomerate’s stock after purchasing an additional 20,113 shares during the period. Danaher accounts for about 1.6% of Riverbridge Partners LLC’s investment portfolio, making the stock its 19th biggest holding. Riverbridge Partners LLC’s holdings in Danaher were worth $53,951,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of the business. Silver Grove Financial Group Inc. increased its position in Danaher by 27.5% in the 3rd quarter. Silver Grove Financial Group Inc. now owns 408 shares of the conglomerate’s stock valued at $90,000 after acquiring an additional 88 shares during the period. AMG National Trust Bank raised its stake in Danaher by 1.9% during the 3rd quarter. AMG National Trust Bank now owns 18,411 shares of the conglomerate’s stock valued at $4,079,000 after acquiring an additional 344 shares during the last quarter. Csenge Advisory Group raised its stake in Danaher by 105.3% during the 3rd quarter. Csenge Advisory Group now owns 4,749 shares of the conglomerate’s stock valued at $1,052,000 after acquiring an additional 2,436 shares during the last quarter. 71 West Capital Partners lifted its position in Danaher by 11.0% during the 3rd quarter. 71 West Capital Partners now owns 4,794 shares of the conglomerate’s stock worth $1,062,000 after acquiring an additional 476 shares during the period. Finally, Montis Financial LLC lifted its position in Danaher by 2.3% during the 3rd quarter. Montis Financial LLC now owns 2,020 shares of the conglomerate’s stock worth $448,000 after acquiring an additional 46 shares during the period. Institutional investors and hedge funds own 79.05% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have weighed in on DHR shares. Stifel Nicolaus lifted their target price on Danaher from $220.00 to $260.00 and gave the company a “buy” rating in a research note on Thursday, October 22nd. Barclays upped their price target on Danaher from $255.00 to $260.00 and gave the stock an “overweight” rating in a research note on Thursday, October 22nd. TD Cowen increased their price target on Danaher from $255.00 to $270.00 and gave the stock a “buy” rating in a report on Thursday, October 22nd. Royal Bank Of Canada lifted their price objective on shares of Danaher from $215.00 to $250.00 and gave the company an “outperform” rating in a research report on Monday, October 5th. Finally, Wall Street Zen upgraded shares of Danaher from a “hold” rating to a “buy” rating in a research report on Monday, October 26th. Eighteen research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $242.91.

Insider Buying and Selling

In other news, CAO Christopher Bouda sold 7,598 shares of the firm’s stock in a transaction that occurred on Wednesday, October 28th. The stock was sold at an average price of $234.56, for a total value of $1,782,186.88. Following the completion of the sale, the chief accounting officer directly owned 9,107 shares of the company’s stock, valued at $2,136,137.92. This trade represents a 45.48% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Gregory Milosevich sold 2,100 shares of Danaher stock in a transaction that occurred on Monday, November 9th. The shares were sold at an average price of $230.62, for a total value of $484,302.00. Following the completion of the sale, the executive vice president owned 22,367 shares in the company, valued at approximately $5,158,277.54. This trade represents a 8.58% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 10.80% of the company’s stock.

Danaher Trading Up 0.6%

NYSE DHR opened at $236.41 on Wednesday. The stock has a market capitalization of $166.32 billion, a P/E ratio of 38.69, a P/E/G ratio of 2.95 and a beta of 0.76. Danaher Corporation has a 52-week low of $160.93 and a 52-week high of $242.80. The firm has a 50-day moving average price of $221.10 and a 200 day moving average price of $201.55. The company has a quick ratio of 1.29, a current ratio of 1.63 and a debt-to-equity ratio of 0.45.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Wednesday, October 21st. The conglomerate reported $2.11 EPS for the quarter, beating analysts’ consensus estimates of $1.92 by $0.19. Danaher had a net margin of 16.91% and a return on equity of 11.17%. The firm had revenue of $6.55 billion during the quarter, compared to the consensus estimate of $6.56 billion. During the same quarter last year, the firm earned $1.89 earnings per share. The firm’s revenue was up 8.3% compared to the same quarter last year. Equities research analysts expect that Danaher Corporation will post 8.59 EPS for the current year.

Danaher Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th were paid a dividend of $0.40 per share. This represents a $1.60 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date of this dividend was Wednesday, September 30th. Danaher’s dividend payout ratio is 26.19%.

Danaher Company Profile

Danaher is a global science and technology company that develops and supplies products and services for biotechnology, life sciences, and diagnostics markets. Its offerings include instruments, reagents, consumables, software, and services used in research, drug development and manufacturing, and clinical testing. The company’s businesses include well-known brands such as Cytiva and Pall in bioprocessing and filtration, Beckman Coulter in laboratory and clinical diagnostics, Cepheid in molecular diagnostics, and Leica Microsystems in microscopy.